Free Trial
NYSEAMERICAN:XTNT

Xtant Medical (XTNT) Stock Price, News & Analysis

Xtant Medical logo
$0.41 0.00 (0.00%)
(As of 11/21/2024 ET)

About Xtant Medical Stock (NYSEAMERICAN:XTNT)

Key Stats

Today's Range
$0.41
$0.42
50-Day Range
N/A
52-Week Range
$0.39
$1.45
Volume
243,159 shs
Average Volume
103,928 shs
Market Capitalization
$57.65 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$2.25
Consensus Rating
Buy

Company Overview

Xtant Medical Holdings, Inc. provides regenerative medicine products and medical devices for orthopedic and neurological surgeons. It offers OsteoSponge that provides a natural scaffold for cellular in-growth and exposes bone-forming proteins to the healing environment; OsteoSelect DBM Putty to mold into any shape and compressed into bony voids; OsteoSelect PLUS DBM Putty to deliver handling properties and ensure patient safety through validated terminal sterilization; 3Demin, a family of allografts that maximizes osteoconductivity and the osteoinductive potential of human bone; OsteoFactor, a processed allograft that contains retained growth factors found within the endosteum layer of allograft bone; OsteoVive Plus, a growth factor enriched cellular bone matrix; and nanOss family of products that provide osteoconductive nano-structured hydroxyapatite and an engineered extracellular matrix bioscaffold collagen carrier. It also processes and distributes sports allografts for anterior and posterior cruciate ligament repairs, anterior cruciate ligament reconstruction, and meniscal repair; milled spinal allografts for cortical bone milled to desired shapes and dimensions; and traditional allografts for orthopedics, neurology, podiatry, oral/maxillofacial, genitourinary, and plastic/reconstructive applications. In addition, it offers Certex spinal fixation, Spider cervical plating, Streamline OCT, CervAlign, Axle interspinous fusion, Xpress minimally invasive pedicle screw, Fortex pedicle screw, Axle-X interspinous fusion, Streamline MIS spinal fixation, Streamline TL spinal fixation systems, and Silex sacroiliac joint fusion systems. Further, it provides Calix for cervical and thoracolumbar applications, as well as Irix-C Cervical Integrated Fusion, Irix-A Lumbar Integrated Fusion, Fortilink, and Irix-A Lumbar integrated fusion systems; Coflex device for lumbar spinal stenosis; and CoFix implant for back and disc pain. The company is headquartered in Belgrade, Montana.

Xtant Medical Stock Analysis - MarketRank™

See Top Rated MarketRank™ Stocks
51st Percentile Overall Score

XTNT MarketRank™: 

Xtant Medical scored higher than 51% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Xtant Medical has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 buy ratings, no hold ratings, and no sell ratings.

  • Amount of Analyst Coverage

    Xtant Medical has only been the subject of 1 research reports in the past 90 days.

  • Read more about Xtant Medical's stock forecast and price target.
  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Xtant Medical is -3.19, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Xtant Medical is -3.19, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    Xtant Medical has a P/B Ratio of 1.26. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

  • Percentage of Shares Shorted

    0.39% of the float of Xtant Medical has been sold short.
  • Short Interest Ratio / Days to Cover

    Xtant Medical has a short interest ratio ("days to cover") of 3.1, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Xtant Medical has recently decreased by 8.44%, indicating that investor sentiment is improving significantly.
  • Dividend Yield

    Xtant Medical does not currently pay a dividend.

  • Dividend Growth

    Xtant Medical does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    0.39% of the float of Xtant Medical has been sold short.
  • Short Interest Ratio / Days to Cover

    Xtant Medical has a short interest ratio ("days to cover") of 3.1, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Xtant Medical has recently decreased by 8.44%, indicating that investor sentiment is improving significantly.
  • News Sentiment

    Xtant Medical has a news sentiment score of -0.24. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.46 average news sentiment score of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 2 news articles for Xtant Medical this week, compared to 1 article on an average week.
  • Insider Buying vs. Insider Selling

    In the past three months, Xtant Medical insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    Only 9.70% of the stock of Xtant Medical is held by insiders.

  • Percentage Held by Institutions

    69.33% of the stock of Xtant Medical is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about Xtant Medical's insider trading history.
Receive XTNT Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Xtant Medical and its competitors with MarketBeat's FREE daily newsletter.

XTNT Stock News Headlines

Xtant Medical Reports Q3 2024 Revenue Growth and New Product Launches
Let’s be blunt
Let me be blunt with you for just a second… You may think you know when and why stocks move, but you’re wrong… Most traders have no idea about the biggest secret Wall Street keeps — even though it’s hiding in plain sight. But once you’ve cracked this code… It could be the breakthrough you need to start targeting $100-$150 a day in the stock market (starting with just $1,000)!
Xtant Medical Hldgs's Earnings Outlook
See More Headlines

XTNT Stock Analysis - Frequently Asked Questions

Xtant Medical Holdings, Inc. (NYSEAMERICAN:XTNT) announced its quarterly earnings data on Tuesday, November, 12th. The medical device company reported ($0.04) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.02) by $0.02. The medical device company had revenue of $27.94 million for the quarter. Xtant Medical had a negative net margin of 15.45% and a negative trailing twelve-month return on equity of 37.07%.

Xtant Medical's stock reverse split before market open on Wednesday, February 14th 2018. The 1-12 reverse split was announced on Tuesday, February 13th 2018. The number of shares owned by shareholders was adjusted after the closing bell on Tuesday, February 13th 2018. An investor that had 100 shares of stock prior to the reverse split would have 8 shares after the split.

Top institutional investors of Xtant Medical include Geode Capital Management LLC (0.37%) and Evernest Financial Advisors LLC (0.03%). Insiders that own company stock include Stavros G Vizirgianakis, Sean E Browne and Scott C Neils.
View institutional ownership trends
.

Shares of XTNT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

Based on aggregate information from My MarketBeat watchlists, some other companies that Xtant Medical investors own include Meta Platforms (META), Aurinia Pharmaceuticals (AUPH), NVIDIA (NVDA), Alibaba Group (BABA), Block (SQ), Tesla (TSLA) and Broadcom (AVGO).

Company Calendar

Last Earnings
11/12/2024
Today
11/21/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Biological products, except diagnostic
Sub-Industry
Pharmaceutical Products
Current Symbol
NYSEAMERICAN:XTNT
Employees
120
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$2.25
High Stock Price Target
$3.00
Low Stock Price Target
$1.50
Potential Upside/Downside
+446.1%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
2 Analysts

Profitability

Net Income
$660,000.00
Pretax Margin
-14.79%

Debt

Sales & Book Value

Annual Sales
$91.30 million
Cash Flow
$0.03 per share
Book Value
$0.33 per share

Miscellaneous

Free Float
125,524,000
Market Cap
$57.27 million
Optionable
Not Optionable
Beta
0.39
2025 Gold Forecast: A Perfect Storm for Demand Cover

Unlock the timeless value of gold with our exclusive 2025 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.

Get This Free Report

This page (NYSEAMERICAN:XTNT) was last updated on 11/21/2024 by MarketBeat.com Staff
From Our Partners